{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:44:35Z","timestamp":1753868675376,"version":"3.41.2"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Current approach to clinically suspicious biopsy\u2010na\u00efve men consists performing prostate MRI, followed by combined systematic (TRUS\u2010Bx) and MRI\u2010Ultrasound fusion biopsy (MRI\u2010TBx) in those with PIRADS score \u2265\u20093. Researchers have attempted to determine who benefits from each biopsy method, but the results do not support the safe use of one method alone. This study aims to determine the optimal approach in biopsy\u2010na\u00efve men, according to their PSA levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results<\/jats:title><jats:p>A retrospective chart review of clinically suspicious biopsy\u2010na\u00efve men who underwent both TRUS\u2010Bx and MRI\u2010TBx was done. Prostate specific antigen (PSA) levels were compared between patients only positive for MRI\u2010TBx and those with positive TRUS\u2010Bx. Further, cancer cases were divided to &lt;\u200910 and \u2265\u200910 PSA groups and the pathology results, obtained by each method, were compared. Out of 195 men, 36 were diagnosed with prostate cancer (PCa). PCa was diagnosed by both MRI\u2010TBx and TRUS\u2010Bx in 26 men, half of whom had PSA\u2009&gt;\u200910\u2009ng\/mL. At PSA \u2264\u200910\u2009ng\/mL, PCa would have been missed in 4 men (11.1%) had MRI\u2010TBx not been done, and in 6 men (16.6%) had TRUS\u2010Bx not been done.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite attempts to perform only one biopsy method in men with clinical suspicion of prostate cancer, we propose that at least in men with PSA \u2264\u200910\u2009ng\/mL, both systematic and MRI\u2010targeted biopsies be performed.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.70099","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T12:21:17Z","timestamp":1737462077000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Value of Systematic and <scp>MRI<\/scp>\u2010Ultrasound Fusion Prostate Biopsy in Different Prostate Specific Antigen (<scp>PSA<\/scp>) Levels"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9745-7063","authenticated-orcid":false,"given":"Solmaz","family":"Ohadian Moghadam","sequence":"first","affiliation":[{"name":"Uro\u2010Oncology Research Center Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Haddadi","sequence":"additional","affiliation":[{"name":"Uro\u2010Oncology Research Center Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erfan","family":"Amini","sequence":"additional","affiliation":[{"name":"Uro\u2010Oncology Research Center Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Ali","family":"Momeni","sequence":"additional","affiliation":[{"name":"Uro\u2010Oncology Research Center Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Bitaraf","sequence":"additional","affiliation":[{"name":"Uro\u2010Oncology Research Center Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Reza","family":"Nowroozi","sequence":"additional","affiliation":[{"name":"Uro\u2010Oncology Research Center Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1191"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.10.044"},{"key":"e_1_2_11_4_1","unstructured":"N.Mottet R. C. N.van denBergh E.Briers et\u00a0al. \u201cEAU\u2010EANM\u2010ESTRO\u2010ESUR\u2010ISUP\u2010SIOG Guidelines on Prostate Cancer \u201d 2022 https:\/\/uroweb.org\/guidelines\/prostate\u2010cancer."},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.11.023"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801993"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.09.007"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.11.037"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2399-z"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.03.002"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.009"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3710"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.004"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30569-2"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209454"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4160"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5531511"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2021.10.002"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.08.018"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.12.012"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2015.09.010"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T15:52:51Z","timestamp":1738252371000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/cnr2.70099"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70099","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"type":"print","value":"2573-8348"},{"type":"electronic","value":"2573-8348"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70099"}}